Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRB-701 in nectin-4 expressing advanced solid tumors
NCT06265727Phase 2Recruiting
- Sponsor
- Corbus Pharmaceuticals Holdings, Inc.
- Start
- Apr 2024
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of CRB-701 in solid tumor (15 arms), sponsored by Corbus Pharmaceuticals Holdings, Inc. Primary endpoints: Maximum Tolerated Dose at 21 days, Pharmacologically Active Dose Range at 21 days and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
CRB-701
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06265727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06265727.